1. Home
  2. TNON vs OGEN Comparison

TNON vs OGEN Comparison

Compare TNON & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenon Medical Inc.

TNON

Tenon Medical Inc.

HOLD

Current Price

$4.52

Market Cap

3.3M

Sector

Health Care

ML Signal

HOLD

Logo Oragenics Inc.

OGEN

Oragenics Inc.

HOLD

Current Price

$0.52

Market Cap

2.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNON
OGEN
Founded
2012
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3M
2.8M
IPO Year
2021
2010

Fundamental Metrics

Financial Performance
Metric
TNON
OGEN
Price
$4.52
$0.52
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.1M
30.6K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
84.90
N/A
EPS
N/A
N/A
Revenue
$3,944,000.00
N/A
Revenue This Year
$65.95
N/A
Revenue Next Year
$50.54
N/A
P/E Ratio
N/A
N/A
Revenue Growth
20.35
N/A
52 Week Low
$0.13
$0.48
52 Week High
$17.84
$1.45

Technical Indicators

Market Signals
Indicator
TNON
OGEN
Relative Strength Index (RSI) 51.70 37.55
Support Level $0.56 $0.49
Resistance Level $7.15 $0.59
Average True Range (ATR) 1.29 0.02
MACD -0.37 -0.00
Stochastic Oscillator 0.86 17.17

Price Performance

Historical Comparison
TNON
OGEN

About TNON Tenon Medical Inc.

Tenon Medical Inc is a medical device company that has minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.

About OGEN Oragenics Inc.

Oragenics Inc is a development-stage biopharmaceutical company dedicated to the research and development of nasal delivery pharmaceutical therapies targeting neurological conditions and infectious diseases. The Company is currently focused on advancing the development and commercialization of its product candidate, ONP-002. ONP-002 is a fully synthetic, non-naturally occurring neurosteroid that is lipophilic and is designed to cross the blood-brain barrier, with the goal of reducing swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The Company's primary focus is on the development and commercialization of ONP-002 for the treatment of mild traumatic brain injury (mTBI), or concussion.

Share on Social Networks: